il-3
Trade name: Muplestim
Recombinant proteinexperimental
IL-3 may refer to:Interleukin 3 Illinois's 3rd congressional district Illinois Route 3 — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 1991 (NCT00001269)
Timeline
1990s
- Jan 1, 1991
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
IL3RA agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIL-3 ↗
- ChEMBLCHEMBL2108469 ↗
Also known as
- hemokine
- human interleukin-3 (nonglycosylated)
- il-3
- interleukin 3
- interleukin-3
- interleukin-3
- interleukin 3 (human)
- interleukin-3 human (recombinant)
- multipotential colony-stimulating factor
- muplestim
- muplestim
- sdz ile 964
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002258 | Phase 1 | Nov 2, 1999 | Sandoz |
| NCT00006225 | Phase 1/Phase 2 (Phase 2) | Nov 1, 1999 | Northwestern University |
| NCT00005787 | Phase 1 | Sep 1, 1999 | National Cancer Institute (NCI), Northwestern University |
| NCT00001269 | Phase 1 | May 1, 1991 | National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 1991 |
| Northwestern University | Academic/Hospital | 2 | 2 | 2 | 1999 |
| Sandoz | For profit | 1 | 1 | 1 | 1999 |
3 organizations
Page 1 / 1